SCHEMBL68772

SCHEMBL68772

O=C1CCC2C=CC=CC2N1

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.30
CRBN Q96SW2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL10621554 0.98 GAA (0.31)
Hydrochloric Acid SCHEMBL10660266 0.96 GAA (0.30)
SCHEMBL460791 0.78 ITGB3 (0.30)
SCHEMBL3147295 0.78
SCHEMBL7099061 0.75
SCHEMBL6087476 0.73
SCHEMBL6232352 0.73 RAB9A (0.31)
SCHEMBL1762422 0.73
SCHEMBL1119401 0.72
SCHEMBL7616392 0.71 SRD5A1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 497 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117695281-B Application of tetrahydroquinolinone-amide-thiazole compound 广州医科大学 2024-06-21 CN claimed
CN-117695281-A Application of tetrahydroquinolinone-amide-thiazole compound 广州医科大学 2024-03-15 CN claimed
CN-111732538-A Tetrahydroquinolinone derivative compounds and application thereof 南京百鑫愉医药有限公司 2020-10-02 CN claimed
US-20200283391-A1 Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases THE UNIVERSITY OF CHICAGO 2020-09-10 US claimed
CN-101657440-B Heterodimers and methods of use thereof BIOTECHNOLOGY RESEARCH Corp.,Ltd. (CN) 2016-01-13 CN claimed
WO-2012139876-A1 ENTERIC FORMULATIONS OF METABOTROPIC GLUTAMATE RECEPTOR MODULATORS MERZ PHARMA GMBH & CO. KGAA (DE) 2012-10-18 WO claimed
CN-101657440-A Heterodimers and methods of use thereof BIOTECHNOLOGY RES CORP LTD HK 2010-02-24 CN claimed
US-7605265-B2 Heterodimers and methods of using them Biotechnology Research Corporation Ltd. (CN) 2009-10-20 US claimed
US-20090176807-A1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF REGAN JOHN ROBINSON 2009-07-09 US claimed
EP-1991234-A2 COMPOSITIONS AND METHODS FOR THE ADMINISTRATION PSYCHOTROPIC DRUGS WHICH MODULATE BODY WEIGHT Azur Pharma III Limited (BM) 2008-11-19 EP claimed
US-20070093471-A1 Compositions and methods for the administration clozapine formulations which modulate body weight ALAMO PHARMACEUTICALS, LLC (US) 2007-04-26 US claimed
EP-1730145-A1 ALPHA-TRIFLUOROMETHYL ALCOHOLS OR AMINES AS GLUCOCORTICOID MIMETICS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-12-13 EP claimed
CN-1735599-A 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands BOEHRINGER INGELHEIM PHARMA (US) 2006-02-15 CN claimed
US-20050234091-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-10-20 US claimed
WO-2005095401-A1 ALPHA-TRIFLUOROMETHYL ALCOHOLS OR AMINES AS GLUCOCORTICOID MIMETICS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-10-13 WO claimed
EP-1583745-A1 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2005-10-12 EP claimed
US-20040162321-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2004-08-19 US claimed
WO-2004063163-A1 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2004-07-29 WO claimed
CN-1038640-A Two ring carboxamide, its preparation methods and contain the pharmaceutical composition of this material BOEHRINGER MANNHEIM GMBH (DE) 1990-01-10 CN claimed
EP-0327986-A2 Medicaments containing lactams, substituted lactams and process for their preparation Roche Diagnostics GmbH (DE) 1989-08-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200283391-A1 Compounds and Methods for Treating, Detecting, and Identifying Compounds to Treat Apicomplexan Parasitic Diseases TUBB1, MYADM, TUBB DDB1 1245/4885CRBN 3793/4885
US-20090176807-A1 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF NR3C1, NR3C2, MC2R DDB1 3664/4885CRBN 2053/4885
US-20050234091-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof NR3C1, MC2R, NR3C2 DDB1 3427/4885CRBN 1884/4885
US-20040162321-A1 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof NR3C1, NR3C2, MC2R DDB1 3428/4885CRBN 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.